[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jinnah Postgraduate Medical Centre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":225},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,76,105,131,155,181,204],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100626659","phase-4-efficacy-of-crisaborole-2-cream-versus-placebo-in-mild-to-moderate-atopic-eczema-100626659",false,"NCT07438509","Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema","Evaluation of the Efficacy of Crisaborole 2% Cream Compared to Placebo in the Management of Mild to Moderate Atopic Eczema","CRISA-AD","Inclusion Criteria:\n\n* Age 12 to 50 years\n* Clinically diagnosed mild to moderate atopic dermatitis (ISGA score 2 or 3)\n* Willing and able to apply topical medication twice daily for four weeks\n* Able to provide written informed consent (parental consent for participants under 18 years)\n\nExclusion Criteria:\n\n* Severe atopic dermatitis (ISGA score 4)\n* Use of systemic corticosteroids, immunosuppressants, or antibiotics within the past two weeks\n* Known hypersensitivity to crisaborole or any component of the formulation\n* Pregnant or lactating women\n* Presence of other significant dermatological conditions that may interfere with evaluation (e.g., psoriasis, scabies)\n* Immunocompromised status (e.g., HIV infection, organ transplant recipient)","ALL","12 Years","50 Years",{"count":21,"type":22},270,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This randomized controlled trial (RCT) aims to evaluate the efficacy and safety of Crisaborole 2% cream compared with placebo in patients with mild to moderate atopic dermatitis (AD), also known as atopic eczema. AD is a chronic inflammatory skin condition characterized by itching, redness, and recurrent flares that can significantly impair quality of life.\n\nEligible participants aged 12 to 50 years with mild to moderate AD will be randomly assigned to receive either Crisaborole 2% cream or a placebo cream applied twice daily for four weeks. The primary outcome is treatment success at Day 28, defined using the Investigator's Static Global Assessment (ISGA) as a score of 0 (clear) or 1 (almost clear) with at least a two-grade improvement from baseline.\n\nParticipants will be evaluated at baseline, Day 14, and Day 28. Safety, tolerability, and compliance will also be assessed. The results of this RCT may provide locally relevant evidence to guide the management of mild to moderate AD.",[28,29],"Atopic Dermatitis (AD)","Atopic Eczema",[31,32,33,34],"Mild to Moderate Atopic Dermatitis","Crisaborole","Phosphodiesterase-4 Inhibitor","Topical Therapy","NOT_YET_RECRUITING","2026-03-04",{"date":38,"type":39},"2026-03-06","ACTUAL",{"date":41,"type":22},"2026-03-01",{"date":43,"type":22},"2026-09-01",{"name":45,"class":46},"Jinnah Postgraduate Medical Centre","OTHER_GOV",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100628307","phase-4-topical-methotrexate-vs-minoxidil-for-localized-alopecia-areata-100628307","NCT07459933","Topical Methotrexate vs Minoxidil for Localized Alopecia Areata","Comparative Study Between Topical Methotrexate 1% Gel and Minoxidil 5% Spray in the Treatment of Localized Alopecia Areata: A Randomized Controlled Trial","MTX-MNX-AA","Inclusion Criteria:\n\nPatients aged 18 to 50 years.\n\nPatients of either gender.\n\n* Patients diagnosed with localized alopecia areata, defined as one or more smooth, well-circumscribed patches of non-scarring hair loss on the scalp with less than 25% scalp involvement, assessed using the Severity of Alopecia Tool (SALT) score.\n* Patients not previously treated with topical methotrexate or minoxidil for alopecia areata.\n* Patients willing to provide written informed consent and comply with follow-up visits.\n\nExclusion Criteria:\n\n* Patients with other types of alopecia, including androgenetic alopecia, telogen effluvium, or scarring alopecia.\n* Patients with systemic diseases that may influence hair growth or treatment response, such as uncontrolled thyroid disease, uncontrolled diabetes mellitus, or autoimmune connective tissue disorders.\n* Pregnant or lactating women.\n* Patients who have used topical or systemic treatment for alopecia areata within the past 3 months.\n* Patients with known hypersensitivity or allergy to methotrexate or minoxidil.","18 Years",{"count":57,"type":22},268,[25],"Alopecia areata is an autoimmune disorder characterized by well-defined, non-scarring patches of hair loss on the scalp and other hair-bearing areas. Although several treatment options are available, there is no universally accepted standard therapy, and treatment responses vary widely among patients.\n\nMinoxidil is commonly used for hair regrowth due to its ability to stimulate hair follicles and prolong the anagen phase of the hair cycle. Methotrexate, an immunosuppressive agent traditionally used in inflammatory and autoimmune diseases, has also been explored as a potential treatment for alopecia areata because of its ability to suppress immune-mediated follicular damage.\n\nThis randomized controlled trial aims to compare the efficacy and safety of topical methotrexate 1% gel versus minoxidil 5% spray in patients with localized alopecia areata. Eligible participants will be randomly assigned to receive either topical methotrexate gel or minoxidil spray and will be followed for 24 weeks. Treatment response will be assessed using the Severity of Alopecia Tool (SALT) score. The findings of this study may help identify an effective therapeutic option for patients with localized alopecia areata and contribute to improving clinical management strategies for this condition.",[61],"Alopecia Areata",[63,64,65,66,67,68],"Localized Alopecia Areata","Topical Methotrexate","Minoxidil 5%","Hair Regrowth","Autoimmune Hair Loss","SALT Score",{"date":70,"type":39},"2026-03-10",{"date":72,"type":22},"2026-03-15",{"date":74,"type":22},"2026-09-15",{"name":45,"class":46},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100623085","phase-4-metronidazole-2-gel-versus-clindamycin-1-gel-for-moderate-acne-vulgaris-100623085","NCT07392047","Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris","Comparison Of The Efficacy Of 2% Metronidazole Gel Versus 1% Clindamycin Gel In The Treatment Of Moderate Acne Vulgaris","METROCLIN","Inclusion Criteria\n\nAdults aged 18-35 years of either sex.\n\nClinical diagnosis of moderate acne vulgaris, defined as a Modified Global Acne Grading System (mGAGS) score of 45-80.\n\nNot currently using any other anti-acne treatment (topical or systemic).\n\nExclusion Criteria\n\nPregnant or lactating women.\n\nSevere acne vulgaris, defined as an mGAGS score \\>80.\n\nKnown hypersensitivity\u002Fallergy to metronidazole or clindamycin (or any component of the study gels).\n\nAny other dermatologic condition affecting the face that may interfere with assessment of acne severity or treatment response.","35 Years",{"count":86,"type":22},60,[25],"Acne vulgaris is a common inflammatory skin disorder. This randomized controlled trial (RCT) will compare the efficacy and safety of 2% metronidazole gel versus 1% clindamycin gel in adults with moderate acne vulgaris at Jinnah Postgraduate Medical Centre (JPMC), Karachi. Sixty eligible participants (18-35 years) will be enrolled using consecutive sampling and randomized in a 1:1 ratio using blocked randomization. Participants will apply the assigned gel as a thin layer twice daily for 12 weeks. Acne severity will be assessed using the Modified Global Acne Grading System (mGAGS) at baseline and at weeks 4, 8, and 12. The primary outcome is the proportion of participants achieving at least a 50% reduction from baseline in total mGAGS score at week 12. Local adverse effects (e.g., erythema, itching, irritation) will be recorded at each follow-up visit.",[90],"Acne Vulgaris",[92,93,94,95,96],"Moderate acne","Metronidazole gel","Clindamycin gel","Topical antibiotic","Modified Global Acne Grading System","2026-02-05",{"date":99,"type":39},"2026-02-06",{"date":101,"type":22},"2026-02",{"date":103,"type":22},"2026-08",{"name":45,"class":46},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100621236","comparative-effectiveness-of-verbal-instruction-versus-simulation-video-education-among-cancer-patients-undergoing-radiation-therapy-100621236","NCT07367997","Comparative Effectiveness of Verbal Instruction Versus Simulation Video Education Among Cancer Patients Undergoing Radiation Therapy","Comparative Effectiveness of Verbal Instruction Versus Simulation Video Education Among Cancer Patients Undergoing Radiation Therapy in Lower Middle Income Country Centre: A Randomized Controlled Trial","CARE-RT","Inclusion Criteria:\n\n* Diagnosed with cancer and scheduled for radiation therapy at Tomotherapy unit of Cyber knife and Tomotherapy Centre of JPMC.\n* Fluent in Urdu.\n* No prior experience with radiation therapy.\n* Must have smart phone\n\nExclusion Criteria:\n\nPatients who either refused consent or were ineligible based on the study's inclusion criteria.",{"count":114,"type":22},100,[116],"NA","The goal of this Randomized Controlled Trial is to compare the effectiveness of radiotherapy-specific, physician-led educational videos introduced before the initial Radiation Therapy consultation .\n\nThe primary objective is to assess the impact on patient-reported knowledge of RT, with secondary objectives including assessment of patient-reported anxiety and satisfaction with the educational process.\n\nPatients will be randomly assigned to two groups.\n\n1. Video Group - Patients will receive a WhatsApp message containing the educational video prior to their consultation.\n2. Verbal Instruction Group - Patients will receive standard verbal education from a radiation oncologist during their consultation.\n\nThe participants will fill Pre and post intervention questionnaire forms",[119,120],"Cancer (Solid Tumors)","Cancer and \u002F or Hematological Malignancy",[122],"Radiation Education","2026-01-20",{"date":125,"type":39},"2026-01-26",{"date":127,"type":22},"2026-01",{"date":129,"type":22},"2026-06",{"name":45,"class":46},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":17,"minAge":55,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100612688","phase-1-comparison-of-efficacy-of-betamethasone-gel-with-lidocaine-gel-in-prevention-of-post-endotracheal-intubation-sore-throat-100612688","NCT07256834","Comparison of Efficacy of Betamethasone Gel With Lidocaine Gel in Prevention of Post Endotracheal Intubation Sore Throat.","Incidence of Sore Throat in Postoperative Patients After Use of Betamethasone Gel Compared With Lidocaine Gel During Endotracheal Intubation","Inclusion Criteria:\n\n1. Patients aged 18-60 years\n2. Either gender\n3. ASA I to II\n4. Patients planned for elective surgery under general anesthesia not lasting more than 4 hours.\n\nExclusion Criteria:\n\n1. Patients requiring more than 2 attempts for successful intubation\n2. Patients undergoing surgeries of oral cavity or pharynx\n3. Mallampati Score of 3 or 4\n4. Patients with upper respiratory tract infection\n5. Patients already taking steroids\n6. Use of nasogastric tube perioperatively",true,"60 Years",{"count":86,"type":22},[142,143],"PHASE1","PHASE2","The goal of this clinical trial is to compare the incidence of postoperative sore throat in adult patients of either gender belonging to ASA I or II ,undergoing endotracheal intubation using betamethasone gel versus lidocaine gel. It aims to determine\n\n1: Difference in efficacy of Betamethasone gel and lidocaine gel in prevention of post operative sore throat after endotracheal intubation.\n\nPatients will be assessed for the presence of a sore throat at 6 hours and 24 hours postoperatively. The severity of the sore throat will be graded using the Post-Operative Sore Throat (POST) score.",[146],"Post Operative Sore Throat at 6hrs and 24hrs After Endotracheal Intubation","2025-11-20",{"date":149,"type":39},"2025-12-01",{"date":151,"type":22},"2025-11-22",{"date":153,"type":22},"2025-12-06",{"name":45,"class":46},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},"100594354","low-dose-oral-minoxdil-in-androgenic-alopecia-100594354","NCT07018349","Low Dose Oral Minoxdil in Androgenic Alopecia","Inclusion Criteria:\n\n* Patients have a clinical and trichoscopic diagnosis of mild to severe AGA\n\nExclusion Criteria:\n\n* Patients who, within three months before the trial, had undergone systemic or topical therapies for AGA\n* People who suffer from additional hair loss conditions such hyperandrogenism, scarring or inflammatory alopecia, or any hormonal disorders.\n* Sensitivity to minoxidil\n* Patients with history of severe systemic diseases (heart, renal, or hepatic), a history of hypertension or hypotension, pregnant and breast-feeding women will also be excluded.\n* Patient who will not be willing to provide written informed consents.","65 Years",{"count":163,"type":22},76,[116],"In order to successfully treat androgenetic alopecia (AGA), this study compares the efficacy of low-dose oral minoxidil dosages of 0.25 mg and 1 mg. It addresses a critical gap in current research, as few studies have examined the relationship between low dosage and outcomes like hair diameter, density, patient satisfaction, and adverse effects, including hypertrichosis. Previous research suggests that low dose of oral minoxidil is a safe and well-tolerated option for hair loss, but the optimal dose for maximizing benefits while minimizing side effects remains unclear. This study aims to determine which dose offers the best balance of efficacy and safety for AGA patients.",[167],"Androgenetic Alopecia (AGA)",[169,170,171],"androgenetic alopecia (AGA)","Minoxdil","Low oral doses","2025-06-10",{"date":174,"type":39},"2025-06-12",{"date":176,"type":22},"2025-06-15",{"date":178,"type":22},"2025-10-20",{"name":45,"class":46},1,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":161,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":203,"locationsCount":4},"100582927","phase-4-efficacy-of-tropical-sertaconazole-nitrate-2-vs-clotrimazole-1-for-tinea-pedis-100582927","NCT06869681","Efficacy of Tropical Sertaconazole Nitrate 2% Vs Clotrimazole 1% for Tinea Pedis","Comparison of Efficacy of Sertaconazole Nitrate Cream 2 Percent Vs Clotrimazole 1 Percent for the Treatment of Tinea Pedis.","Inclusion Criteria:\n\n* Patients of age 18-65 years age.\n* Either sex.\n* Patients presenting with the clinical manifestations of tinea pedis such as erythema, scaling, vesicles, pustules, and itch.\n* Skin scrapings positive for KOH mount test.\n\nExclusion Criteria:\n\n* Patients with secondary bacterial infection.\n* Patients using topical or taken any oral antifungal drug before the baseline visit.\n* Diabetic, immunocompromised patients.\n* Women with pregnancy or lactating mothers.\n* Patients allergic to the drugs in this study.\n* Those who withdrew in the middle of the study, or changed drugs without authorization will also be excluded.",{"count":114,"type":22},[25],"This randomized controlled trail study will be carried out on OPD patients in the Department of Dermatology, Jinnah Postgraduate Medical Center. Institutional Ethical committee permission will be obtained and clinical trial registration number (CTN) will be obtained for the study. Written consent will obtained from all the participants of the study.\n\nAll the diagnosed patients of Tinea Pedis who will meet the selection criteria will be enrolled and will be educated regarding the study. Participants will be randomly allocated in into two groups utilizing envelop method; patients of Group-A will use topical Sertaconazole 2% and patients in Group-B will use Clotrimazole 1%.\n\nRandomization: Random number sequence will be generated on computer by a simple randomization schedule. Each randomization number will be sealed in an opaque envelope with a serial number on it. The patient with a known serial number opened the corresponding envelope to be informed of the assignment.\n\nTreatment: After cleaning the identified lesions, the patients will topically self-apply the both products\u002Fcreams using a cotton swab applicator, where the applied amount will be able to make the lesions be covered with a thin layer of medication. Both the creams will be applied topically twice daily for 4 weeks.\n\nPatients will be followed up weekly for clinical improvement and side-effects of therapy upto 4 weeks of the treatment. At final follow up (after 4 week of treatment), the patients will be evaluated by all clinical investigations and microscopic examination (10% potassium hydroxide) of a skin scraping from site of the lesion. Adverse effects of the drugs among all patients will also be recorded. The photograph of the lesions taken before treatment and at the end of the study will be used for assessing the clinical improvement of the cases.\n\nDetailed questionnaires will be followed regarding demographic and clinical characteristics like age, BMI, symptoms and co morbidities etc. Proper selection criteria will be used to control any biasness. Efficacy will be reported as per operational definition. In case of, topical therapy will be terminated and the concerned patient will be switched over to an oral antifungal drug at the discretion of the dermatologist. Any adverse events during the study will also be reported.",[192],"Tinea Pedis",[192,194,195,196],"Efficacy","Sertaconazole Nitrate Cream","Clotrimazole","2025-03-05",{"date":199,"type":39},"2025-03-11",{"date":201,"type":22},"2025-03-01",{"date":176,"type":22},{"name":45,"class":46},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":161,"enrollmentInfo":210,"targetDuration":4,"studyType":211,"phases":4,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":180},"100577648","efficacy-of-injection-sekucinumab-in-erythrodermic-psoriasis-100577648","NCT06801028","Efficacy of Injection Sekucinumab in Erythrodermic Psoriasis","Inclusion criteria:\n\n* Patients of age 18-65 years age.\n* Either sex.\n* Patients presenting with the clinical manifestations of Erythrodermic Psoriasis such as redness, inflammation, skin rash, erythema, scaling, and itch on more than 90% of body surface area.\n\nExclusion criteria:\n\n* Patients of pediatric age.\n* Erythroderma caused by a condition other than psoriasis.\n* Patient treated with biologics for a different condition other than EP.\n* Diabetic, immunocompromised patients.\n* Women with pregnancy or lactating mothers.\n* Patients allergic to the drugs in this study.",{"count":86,"type":22},"OBSERVATIONAL","Erythroderma is a rare and severe dermatological manifestation of a variety of diseases. The most common form of erythroderma is erythrodermic psoriasis (EP), which accounts for 1-2.25% of all psoriatic patients, with a male predominance as demonstrated by a male to female ratio of 3:1. EP clinically manifests with diffuse erythema involving also skin folds with or without exfoliate dermatitis. Secukinumab is a FDA approved biological targeting interleukin-17A (IL17A) cytokine used in the treatment of moderate-to-severe psoriasis. Many clinical trials have been undertaken to establish its efficacy and safety in psoriasis. Numerous studies have highlighted the efficacy and safety of secukinumab. Secukinumab yields rapid and sustained improvements of signs and symptoms in patients EP. Secukinumab also had the lowest treatment cost compared with other biologic treatments for moderate to severe psoriasis. Secukinumab is a monoclonal antibody targeting IL-17, a key player in psoriasis pathogenesis, making it highly effective for psoriasis management. Erythrodermic psoriasis (EP) is a rare, severe form of the disease, affecting over 90% of the body, with significant health risks like electrolyte imbalance and infection. Treatment options for EP are not standardized due to its rarity, and conventional therapies such as acitretin, ciclosporin, and methotrexate have limited efficacy and tolerance issues. While biologics are well-studied for plaque psoriasis, data on EP is scarce. This study aims to evaluate secukinumab's efficacy in EP and explore factors influencing treatment outcomes.",[214],"Erythrodermic Psoriasis",[214,194,216],"Sekucinumab","2025-01-23",{"date":219,"type":39},"2025-01-30",{"date":221,"type":22},"2025-01-20",{"date":223,"type":22},"2025-05-30",{"name":45,"class":46},""]